Hair loss is most often framed as a male problem. The imagery is familiar: a receding hairline, a bald crown. But the reality is that hair thinning and shedding affects a significant proportion of women — and the experience tends to be more diffuse, more emotionally loaded, and far less discussed in mainstream media or clinical settings.
If you're noticing more hair in the shower drain, a widening part, or a ponytail that's noticeably thinner than it used to be: this is for you.
The scale of the problem
Estimates suggest that up to 40% of women experience noticeable hair loss by age 50. The prevalence increases post-menopause, but it's not exclusively a mid-life issue — androgenetic alopecia in women can begin in the 20s or 30s, and can be significantly accelerated by hormonal events including pregnancy, postpartum recovery, coming off hormonal contraception, and conditions like PCOS or thyroid dysfunction.
Despite how common it is, female hair loss remains clinically undertreated and socially minimised. Most research and most pharmaceutical development has been focused on men.
What causes hair loss in women?
The causes are not always identical to male hair loss, though there is significant overlap. The most common drivers include:
Androgenetic alopecia (hormonal hair loss)
Contrary to popular belief, DHT-driven hair loss is not exclusive to men. Women produce androgens too — in the ovaries and adrenal glands — and follicles that are genetically sensitive to DHT will respond to it regardless of sex.
In women, androgenetic alopecia tends to present differently than in men. Rather than a receding hairline, it typically causes diffuse thinning across the crown and top of the scalp, with the frontal hairline often preserved. The Ludwig Classification scale is used to grade female pattern hair loss from Grade I (minimal thinning) to Grade III (pronounced thinning with visible scalp).
The mechanism is the same: 5-alpha reductase converts testosterone to DHT at the follicle, DHT binds to androgen receptors, and genetically predisposed follicles progressively miniaturise over successive cycles.
Telogen effluvium
This is a shedding pattern triggered by systemic stress — physical or emotional. The body, in response to the stressor, shifts a large number of follicles from the growth phase into the resting phase simultaneously. Six to twelve weeks later, those follicles shed in a wave.
Common triggers include: major illness or surgery, significant weight loss, iron deficiency, thyroid dysfunction, childbirth, and high psychological stress. Telogen effluvium is generally reversible once the underlying trigger is addressed — but if the trigger is chronic, shedding can become persistent.
Hormonal fluctuation
Oestrogen and progesterone play a protective role in the hair cycle — they prolong the anagen phase and counterbalance androgen activity at the follicle. When oestrogen drops — at menopause, postpartum, or when coming off combined oral contraceptives — androgens have relatively more influence, and genetically susceptible follicles respond accordingly.
PCOS (polycystic ovary syndrome) deserves specific mention. Elevated androgens are a hallmark feature of PCOS, and androgenetic alopecia is among the most common dermatological manifestations. For women with PCOS, hair loss is often accompanied by other signs of androgen excess.
Nutritional deficiency
Iron, ferritin, zinc, vitamin D, and protein are all implicated in hair cycle health. Deficiency — even subclinical deficiency that doesn't register as anaemia on standard blood panels — can impair follicle function. This is particularly common in women, given menstrual iron losses and the dietary patterns more prevalent in female populations.
What the evidence says about intervention
The honest answer is that the evidence base for female hair loss is thinner than it should be, given how common the condition is. That said, there are approaches with meaningful clinical support:
5-Alpha reductase inhibitors (topical): Because systemic finasteride carries risks for women of reproductive age, topical approaches that inhibit 5-AR locally — without systemic hormonal effects — are clinically preferable. Topical saw palmetto extract has been studied in this context with positive outcomes.
Minoxidil (2% or 5% topical): The only FDA-approved topical treatment for female pattern hair loss. It works primarily through vasodilation (similar to the nitric oxide pathway supported by Arginine HCL) and by extending the anagen phase. Most effective when begun early.
Scalp-targeted actives: The combination of DHT management, improved microcirculation, follicle signalling (via peptides like Sh-Polypeptide-1), and antioxidant protection addresses multiple mechanisms simultaneously — which matters because female hair loss is rarely a single-mechanism condition.
Addressing underlying drivers: Treating iron deficiency, thyroid dysfunction, or managing PCOS hormonally creates the foundation without which topical intervention is unlikely to produce full results.
Why Vyla was built with women in mind
The Vyla Peptide Hair Oil was formulated for the reality of how hair loss presents in women — diffuse, hormonally influenced, and occurring against a background of multiple contributing factors. Every active has a defined role: Sh-Polypeptide-1 for follicle signalling, Saw Palmetto for DHT management, Arginine HCL for scalp circulation, Scutellaria Baicalensis for antioxidant and anti-inflammatory protection.
No product is a replacement for investigating and addressing root causes. But a topical formulation that works at the right level of biology — the follicle — is a meaningful part of a complete approach.
You deserve to understand what's happening and why. And you deserve products that take the science seriously.